Gilead snags FDA green light for 4-in-1 HIV combo

Gilead ($GILD) is facing mounting competition in the HIV space from players including GlaxoSmithKline's ($GSK) ViiV Healthcare. But now, it has a new combo product to tout in Genvoya, which won an FDA go-ahead Thursday. The pill--which combines emtricitabine, marketed as Emtriva; cobicistat, known as Tybost; elvitegravir, dubbed Vitekta; and investigational med tenofovir alafenamide--is approved for patients with HIV genotype 1 who have either never taken an antiviral or whose virus is already suppressed. Release | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.